Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, announced that interim clinical data from an ongoing Phase I study of BBT-176 has been selected for a mini oral presentation at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer (IASLC WCLC 2022), Aug. 6-9 in Vienna.
Also Read: GenomOncology Selected by Personalis to Support MRD and SNV Analysis for NeXT Personal Assay
The oral presentation, to be delivered by Sun Min Lim, M.D., Ph.D., assistant professor at Yonsei University College of Medicine, will discuss interim clinical data from the Phase I study of BBT-176 in advanced non-small cell lung cancer (NSCLC) patients harboring an EGFR mutation who were previously treated with at least one epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). According to the published abstract, the presentation will cover potent anti-tumor efficacy of BBT-176 explored with radiological improvements in both target and non-target lesions from two patients harboring EGFR triple mutations of exon 19 del/T790M/C797S.
One patient from the 320mg dosing cohort exhibited 30.3 percent shrinkage of the target lesion, according to the abstract. Another patient from the 480mg dosing cohort exhibited 26.3 percent shrinkage of the target lesion. Investigators will explore the recommended Phase 2 dose (RP2D) based on the overall safety, efficacy and tolerability information collected in the Phase 1 clinical study.
Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs including ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.